TransMedics Group (NASDAQ:TMDX) Price Target Raised to $80.00

TransMedics Group (NASDAQ:TMDX) had its price objective increased by analysts at Stifel Nicolaus from $75.00 to $80.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “hold” rating on the stock. Stifel Nicolaus’ target price points to a potential upside of 9.26% from the company’s previous close.

Several other analysts have also recently issued reports on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of TransMedics Group in a report on Tuesday, June 9th. Needham & Company LLC cut their price target on shares of TransMedics Group from $174.00 to $142.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Canaccord Genuity Group cut their price target on shares of TransMedics Group from $152.00 to $124.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Piper Sandler cut their price target on shares of TransMedics Group from $160.00 to $120.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. Finally, JPMorgan Chase & Co. upped their price target on shares of TransMedics Group from $114.00 to $149.00 and gave the company a “neutral” rating in a report on Wednesday, February 25th. Six investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $134.50.

TransMedics Group Trading Down 3.4%

NASDAQ TMDX opened at $73.22 on Thursday. The company’s fifty day simple moving average is $84.57 and its 200-day simple moving average is $113.51. TransMedics Group has a 52 week low of $60.10 and a 52 week high of $156.00. The company has a current ratio of 6.74, a quick ratio of 6.19 and a debt-to-equity ratio of 1.70. The stock has a market cap of $2.53 billion, a P/E ratio of 16.64 and a beta of 1.91.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Tuesday, May 5th. The company reported $0.30 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). The firm had revenue of $173.93 million for the quarter, compared to analyst estimates of $174.44 million. TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The company’s revenue for the quarter was up 21.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.70 earnings per share. Equities research analysts predict that TransMedics Group will post 1.98 EPS for the current fiscal year.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of the stock in a transaction on Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the sale, the director directly owned 16,642 shares of the company’s stock, valued at approximately $1,249,148.52. This represents a 36.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 6.90% of the company’s stock.

Institutional Trading of TransMedics Group

Institutional investors and hedge funds have recently modified their holdings of the business. Harvest Fund Management Co. Ltd acquired a new stake in shares of TransMedics Group during the third quarter worth $29,000. Allworth Financial LP raised its holdings in shares of TransMedics Group by 74.3% during the third quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after purchasing an additional 113 shares during the period. Optiver Holding B.V. raised its holdings in shares of TransMedics Group by 248.1% during the third quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock worth $30,000 after purchasing an additional 191 shares during the period. Parallel Advisors LLC raised its holdings in shares of TransMedics Group by 42.1% during the fourth quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock worth $34,000 after purchasing an additional 83 shares during the period. Finally, Ascentis Independent Advisors acquired a new stake in shares of TransMedics Group during the first quarter worth $30,000. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post?transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.